Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by Harbin Medical University.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Harbin Medical University
Information provided by:
Harbin Medical University
ClinicalTrials.gov Identifier:
NCT01024179
First received: December 1, 2009
Last updated: December 4, 2009
Last verified: December 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Vulnerable plaque characterized by thin fibrous cap and large lipid core is an independent risk factor for most of acute cardiac event. Current clinical data showed that thin-cap fibroatheroma was more frequently observed in patients with ACS than SAP. Further OCT study indicated that patients with ACS had significantly higher incidence of incomplete neointimal coverage and malapposition after DES implantation than those with SAP. These findings imply that initial native lesion characteristics may be related to different vessel response (neointimal coverage and malapposition) after stenting. However, there is little data on the relationship between plaque characteristics and vascular response to DES after stent implantation evaluated by OCT.
Therefore, this study was designed to investigate the relationship between initial plaque characteristics and stent surface coverage or late malapposition after SES implantation. The investigators will use high resolution OCT to assess the initial culprit plaque morphology and subsequent vascular response after SES stenting at the time points of post-stenting, 6 months and 12 months. IVUS will also be performed to evaluate the tissue protrusion, malapposition, vessel remodeling at the same time points.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Artery Disease |
Device: Polymer-based sirolimus-eluting stent (Partner stent ) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography |
Resource links provided by NLM:
Further study details as provided by Harbin Medical University:
Primary Outcome Measures:
- To investigate the relationship between initial plaque characteristics and stent surface coverage after sirolimus-eluting stent implantation. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Relationship between tissue prolapse and initial plaque characteristics [ Time Frame: Post-intervention ] [ Designated as safety issue: Yes ]
- Comparison of the differences in vascular response (surface coverage and malapposition) between CTO and non- CTO lesions. [ Time Frame: 6-month ] [ Designated as safety issue: Yes ]
- Late stent malapposition( by OCT and IVUS ). [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Relationship between initial lesion characteristics and stent surface coverage pattern after SES implantation. [ Time Frame: 12 -month ] [ Designated as safety issue: Yes ]
- Comparison of the differences in stent surface coverage between CTO and non- CTO lesions. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 90 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Group B: CTO
Chronic total occlusion
|
Device: Polymer-based sirolimus-eluting stent (Partner stent )
Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
|
|
Active Comparator: Group A : Non-CTO
Non-chronic total occlusion :
|
Device: Polymer-based sirolimus-eluting stent (Partner stent )
Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
General Inclusion Criteria：
- Age:18-75Y
- Patients with stable angina or acute coronary syndrome considered suitable for coronary revascularization.
- Patient or legal guardian understands and agrees to comply with all specified study requirements and provides written informed consent.
Angiographic Inclusion Criteria：
- Significant coronary de novo lesion (> 70% by visual estimation).
- Target lesion is de novo native coronary artery lesion that can be treated with 1-2 stents.
- Reference vessel diameter of 2.5 to 4.0 mm.
Exclusion Criteria：
General Exclusion Criteria：
- ST-segment elevation myocardial infarction within 7 days prior to the index procedure.
- Previous CABG.
- Life expectancy <12 months due to another medical condition.
- Contraindication to antiplatelet therapy
- Creatinine level more than 2.0mg/dL or ESRD.
- Severe hepatic dysfunction (more than 3 times normal reference values).
- Planned surgery procedure ≤ 6 months post-index procedure.
- Known allergy to stainless steel or a history of hypersensitivity to sirolimus or structurally related compounds.
- Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure, or lactating, or intends to become pregnant during the 12 months post index procedure.
- Patient is not clinically appropriate for OCT evaluation in the opinion of the investigator.
Angiographic Exclusion Criteria：
- Study lesion is ostial in location (within 3.0 mm of vessel origin).
- Study lesion involving arterial segments with highly tortuous anatomy.
- Complex lesion morphologies (aorto-ostial, bifurcation needs two stents technique, left main, severe thrombi, heavy calcification).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01024179
Contacts
| Contact: Bo Yu, MD,PhD | 86-0451-86605180 | yubodr@163.com |
Locations
| China, Heilong jiang | |
| The second Affiliated Hospital of Harbin Medical University | Recruiting |
| Harbin, Heilong jiang, China, 150081 | |
| Contact: Bo Yu, MD.PhD 86-0451-86605180 yubodr@163.com | |
| Principal Investigator: Bo Yu, MD,PhD | |
Sponsors and Collaborators
Harbin Medical University
Investigators
| Principal Investigator: | Bo Yu, MD.PhD | The Second Affiliated Hospital of Harbin Medical University |
More Information
No publications provided
| Responsible Party: | Bo Yu, Department of Cardiology of The Second Affiliated Hospital of Harbin Medical University |
| ClinicalTrials.gov Identifier: | NCT01024179 History of Changes |
| Other Study ID Numbers: | HMUOCT-PLAQUE |
| Study First Received: | December 1, 2009 |
| Last Updated: | December 4, 2009 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Harbin Medical University:
|
Optical Coherence Tomography Coronary artery disease Chronic total occlusion |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Sirolimus Everolimus |
Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on May 22, 2013